Department of Medicine, Faculty of Medicine, Kuwait; Department of Hematology, Kuwait Cancer Center, Kuwait.
Department of Hematology, Kuwait Cancer Center, Kuwait.
Leuk Res. 2021 Nov;110:106668. doi: 10.1016/j.leukres.2021.106668. Epub 2021 Jul 15.
Chronic lymphocytic leukemia (CLL) is uncommon in the Middle East. There is limited data on the prognosis and of CLL in this region.
This was a retrospective study (2009-2020) of consecutively diagnosed patients with CLL at Kuwait Cancer Center. The diagnosis, prognosis, treatment indication, response criteria, and adverse events were recorded per International Workshop on Chronic Lymphocytic Leukemia guidelines.
A total of 219 patients with CLL were enrolled in the study. The crude annual incidence is 0.4 per 100,000. The median follow-up was 120 months. The median age at diagnosis was 59 years, and 32 % of patients with CLL were ≤ 55 years of age. Prognostic fluorescence in situ hybridization data were available in 213 cases. del (13q14/13q34) was found in 80 (31 %) cases, del (11q) in 23 (10.7 %) cases, del (17p) in 11 (5.16 %) cases, and trisomy 12 in 46 (21.5 %) cases. IGHV mutation status was available in 92 cases, 45 of which (48.9) were mutated and 47 (51.1 %) of which were not. The median progression-free survival (PFS) for the entire cohort was 178 months [95 % CI: 145-NE].· The median OS was 203 months [95 % CI: 145-NE]. The median PFS for the IGHV mutated cases was not reached [95 % CI: 178 - NE]; while the median PFS for the unmutated CLL cases was 24 months [95 % CI: 124 - NE].
CLL is a rare hematological malignancy in the Middle East. Our CLL cohort is younger and expresses less del13q, but has similar rates of IGHV mutations.
慢性淋巴细胞白血病（CLL）在中东并不常见。关于该地区 CLL 的预后数据有限。
这是一项回顾性研究（2009 年至 2020 年），在科威特癌症中心连续诊断患有 CLL 的患者。根据国际慢性淋巴细胞白血病工作组的指南，记录了诊断、预后、治疗指征、反应标准和不良事件。
共有 219 例 CLL 患者入组研究。粗发病率为每年 0.4/10 万。中位随访时间为 120 个月。诊断时的中位年龄为 59 岁，32%的 CLL 患者年龄≤55 岁。213 例患者有预后荧光原位杂交数据。80 例（31%）存在 del（13q14/13q34），23 例（10.7%）存在 del（11q），11 例（5.16%）存在 del（17p），46 例（21.5%）存在三体 12。IGHV 突变状态在 92 例患者中可用，其中 45 例（48.9%）为突变，47 例（51.1%）为非突变。整个队列的中位无进展生存期（PFS）为 178 个月[95%CI：145-NE]。中位总生存期（OS）为 203 个月[95%CI：145-NE]。IGHV 突变病例的中位 PFS 未达到[95%CI：178-NE]；而未突变 CLL 病例的中位 PFS 为 24 个月[95%CI：124-NE]。
CLL 在中东是一种罕见的血液系统恶性肿瘤。我们的 CLL 队列更年轻，表达较少的 del13q，但 IGHV 突变率相似。
